Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Critical Care
Erschienen in: Critical Care 5/2005

01.10.2005 | Review

Bench-to-bedside review: Antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit

verfasst von: Marin H Kollef

Erschienen in: Critical Care | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Antimicrobial resistance has emerged as one of the most important issues complicating the management of critically ill patients with infection. This is largely due to the increasing presence of pathogenic microorganisms with resistance to existing antimicrobial agents resulting in the administration of inappropriate treatment. Effective strategies for the prevention of antimicrobial resistance within intensive care units are available and should be aggressively implemented. The importance of preventing antimicrobial resistance is magnified by the limited availability of new antimicrobial drug classes for the foreseeable future.
Literatur
1.
Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996, 275: 234-240. 10.1001/jama.275.3.234CrossRefPubMed
2.
Carlet J, Ben Ali A, Chalfine A: Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004, 17: 309-316. 10.1097/01.qco.0000136927.29802.68CrossRefPubMed
3.
Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M: The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study; EPIC International Advisory Committee. JAMA 1995, 274: 639-644. 10.1001/jama.274.8.639CrossRefPubMed
4.
Waldvogel FA: New resistance in Staphylococcus aureus . N Engl J Med 1999, 340: 556-557. 10.1056/NEJM199902183400709CrossRefPubMed
5.
Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ: Antibiotic susceptibility among aerobic Gram-negative Bacilli in intensive care units in 5 European countries. JAMA 1999, 281: 67-71. 10.1001/jama.281.1.67CrossRefPubMed
6.
Quinn JP: Clinical problems posed by multiresistant nonfer-menting gram-negative pathogens. Clin Infect Dis 1998, 27: S117-S124.CrossRefPubMed
7.
Jones RN, Sader HS, Beach ML: Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001). Int J Antimicrob Agents 2003, 22: 551-556. 10.1016/S0924-8579(03)00245-0CrossRefPubMed
8.
Livermore DM: Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003, 36: S11-S23. 10.1086/344654CrossRefPubMed
9.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.: Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32: 858-873. 10.1097/01.CCM.0000117317.18092.E4CrossRefPubMed
10.
Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, et al.: Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997, 25: 584-599.CrossRefPubMed
11.
Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP: Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003, 289: 885-888. 10.1001/jama.289.7.885CrossRefPubMed
12.
Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997, 24: 211-215.CrossRefPubMed
13.
Sieradzki K, Roberts RB, Haber SW, Tomasz A: The development of Vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999, 340: 517-523. 10.1056/NEJM199902183400704CrossRefPubMed
14.
Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robin-son-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, et al.: Emergence of Vancomycin resistance in Staphylococcus aureus . N Engl J Med 1999, 340: 493-501. 10.1056/NEJM199902183400701CrossRefPubMed
15.
Van Looveren M, Goossens H: Antimicrobial resistance of Acinetobacter spp . in Europe. Clin Microbiol Infect 2004, 10: 684-704. 10.1111/j.1469-0691.2004.00942.xCrossRefPubMed
16.
Canton R, Coque TM, Baquero F: Multi-resistant Gram-negative bacilli: from epidemics to endemics. Curr Opin Infect Dis 2003, 16: 315-325.CrossRefPubMed
17.
Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D: Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa . Clin Infect Dis 2003, 11: 154-160. 10.1086/379611CrossRef
18.
Livermore DM, Yuan M: Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp from intensive care units in Europe. J Antimicrob Chemother 1996, 38: 409-424.CrossRefPubMed
19.
Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A: Association of Hospital Bacteriologists, Virologists and Hygiene Professionals. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004, 10: 448-451. 10.1111/j.1469-0691.2004.00830.xCrossRefPubMed
20.
Haley RW, Bregman DA: The role of understaffing and overcrowding in recurrent outbreaks of staphylococcal infection in a neonatal special-care unit. J Infect Dis 1982, 145: 875-885.CrossRefPubMed
21.
Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit. Ann Intern Med 2001, 134: 298-314.CrossRefPubMed
22.
Kollef MH, Micek ST: Strategies to prevent antimicrobial resistance in the ICU. Crit Care Med 2005, in press.
23.
Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C: Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture technique. Am Rev Respir Dis 1989, 139: 877-884.CrossRefPubMed
24.
Ortiz J, Vila MC, Soriano G, Minana J, Gana J, Mirelis B, Novella MT, Coll S, Sabat M, Andreu M, et al.: Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cir-rhotic patients. Hepatology 1999, 29: 1064-1069. 10.1002/hep.510290406CrossRefPubMed
25.
Kaplan SL, Mason EO Jr, Barson WJ, Wald ER, Arditi M, Tan TQ, Schutze GE, Bradley JS, Givner LB, Kim KS, et al.: Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics 1998, 102: 538-545. 10.1542/peds.102.3.538CrossRefPubMed
26.
Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20: 1126-1133.CrossRefPubMed
27.
Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JK, Gordon SM: Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubed patients. Chest 1999, 115: 1378-1382. 10.1378/chest.115.5.1378CrossRefPubMed
28.
Rello J, Ausina V, Ricart M, Castella J, Prats G: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993, 104: 1230-1235.CrossRefPubMed
29.
Kollef MH: Ventilator-associated pneumonia: a multivariate analysis. JAMA 1993, 270: 1965-1970. 10.1001/jama.270.16.1965CrossRefPubMed
30.
Kollef MH, Silver P, Murphy DM, Trovillion E: The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995, 108: 1655-1662.CrossRefPubMed
31.
Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N, Marks S, Burns JM, Dominick D, et al.: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella . JAMA 1998, 280: 1233-1237. 10.1001/jama.280.14.1233CrossRefPubMed
32.
Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993, 119: 353-358.CrossRefPubMed
33.
Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, Rahal JJ: Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype antratus. J Infect Dis 1993, 167: 448-451.CrossRefPubMed
34.
Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998, 157: 531-539.CrossRefPubMed
35.
Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, et al.: Comparison of 15 vs. 8 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290: 2588-2598. 10.1001/jama.290.19.2588CrossRefPubMed
36.
Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001, 163: 1371-1375.CrossRefPubMed
37.
Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118: 146-155. 10.1378/chest.118.1.146CrossRefPubMed
38.
Harbarth S, Ferriere K, Hugonnet S, Ricou B, Suter P, Pittet D: Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002, 137: 1353-1359. 10.1001/archsurg.137.12.1353CrossRefPubMed
39.
Alvarez-Lerma F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996, 22: 387-394. 10.1007/BF01712153CrossRefPubMed
40.
Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29: 1109-1115. 10.1097/00003246-200106000-00003CrossRefPubMed
41.
Kollef MH: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31: S131-S138. 10.1086/314079CrossRefPubMed
42.
Kollef MH, Sherman G, Ward S, Prentice D, Schaiff R, Huey W, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115: 462-474. 10.1378/chest.115.2.462CrossRefPubMed
43.
Kollef MH, Ward S: The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998, 113: 412-420.CrossRefPubMed
44.
Rello J, Gallego M, Mariscal D, Sonora R, Valles J: The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156: 196-200.CrossRefPubMed
45.
Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111: 676-685.CrossRefPubMed
46.
Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49: 1306-1311. 10.1128/AAC.49.4.1306-1311.2005PubMedCentralCrossRefPubMed
47.
Dhainaut JF, Laterre PF, LaRosa S, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, et al.: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003, 31: 2291-2301. 10.1097/01.CCM.0000085089.88077.AFCrossRefPubMed
48.
Harbarth S, Garbino JK, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effects on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005CrossRefPubMed
49.
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31: 2742-2751. 10.1097/01.CCM.0000098031.24329.10CrossRefPubMed
50.
Micek ST, Isakow W, Shannon W, Kollef MH: Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Pharmacotherapy 2005, 25: 26-34. 10.1592/phco.25.1.26.55615CrossRefPubMed
51.
Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP: Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997, 277: 301-306. 10.1001/jama.277.4.301CrossRefPubMed
52.
Evans RS, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP: Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994, 154: 878-884. 10.1001/archinte.154.8.878CrossRefPubMed
53.
Pestotnik SL, Classen DC, Evans RS, Burke JP: Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996, 124: 884-890.CrossRefPubMed
54.
Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, Lloyd JF, Burke JP: A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998, 338: 232-238. 10.1056/NEJM199801223380406CrossRefPubMed
55.
Bailey TC, Ritchie DJ, McMullin ST, Kahn M, Reichley RM, Casabar E, Shannon W, Dunagan WC: A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy 1997, 17: 277-281.PubMed
56.
Micek ST, Ward S, Fraser VJ, Kollef MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125: 1791-1799. 10.1378/chest.125.5.1791CrossRefPubMed
57.
McGowan JE Jr, Gerding DN: Does antibiotic restriction prevent resistance? New Horizons 1996, 4: 370-376.PubMed
58.
Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM: Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile -associated diarrhea and cost. Ann Intern Med 1998, 128: 989-995.CrossRefPubMed
59.
Quale J, Landman D, Atwood E, Kreiswirth B, Willey BM, Ditore V, Zaman M, Patel K, Saurina G, Huang W, et al.: Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996, 24: 372-379. 10.1016/S0196-6553(96)90025-5CrossRefPubMed
60.
Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R, Singer DE, Coley CM, Marrie TJ, Fine MJ: Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997, 278: 32-39. 10.1001/jama.278.1.32CrossRefPubMed
61.
Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R: Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999, 159: 266-270. 10.1001/archinte.159.3.266CrossRefPubMed
62.
McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, Bannerjee M, Cartwright KA: Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997, 40: 707-711. 10.1093/jac/40.5.707CrossRefPubMed
63.
Wade JC: Antibiotic therapy for the granulocytopenic cancer patient: combination therapy vs. monotherapy. Rev Infect Dis 1989, 11: S1572-S1581.CrossRefPubMed
64.
Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L: Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004, 328: 668. 10.1136/bmj.38028.520995.63PubMedCentralCrossRefPubMed
65.
Paul M, Soares-Weiser K, Leibovici L: Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003, 326: 1111. 10.1136/bmj.326.7399.1111PubMedCentralCrossRefPubMed
66.
Chamot E, Boffi El Amari E, Rohner P, Van Delden C: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003, 47: 2756-2764. 10.1128/AAC.47.9.2756-2764.2003PubMedCentralCrossRefPubMed
67.
Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162: 505-511.CrossRefPubMed
68.
Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA: Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000, 283: 1583-1590. 10.1001/jama.283.12.1583CrossRefPubMed
69.
Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB: High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003, 37: 752-760. 10.1086/377539CrossRefPubMed
70.
Niederman MS: Is 'crop rotation' of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med 1997, 156: 1029-1031.CrossRefPubMed
71.
Gruson D, Hilbert G, Vargas F, Valentino R, Bebear C, Allery A, Bebear C, Gbikpi-Benissan G, Cardinaud JP: Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000, 162: 837-843.CrossRefPubMed
72.
Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V: Scheduled rotation of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 1997, 156: 1040-1048.CrossRefPubMed
73.
Kollef MH, Ward S, Sherman G, Prentice D, Schaiff R, Huey W, Fraser V: Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000, 28: 3456-3464. 10.1097/00003246-200010000-00014CrossRefPubMed
74.
Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG: Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003, 31: 1035-1041. 10.1097/01.CCM.0000060015.77443.31CrossRefPubMed
75.
Hughes MG, Evans HL, Chong TW, Smith RL, Raymond DP, Pel-letier SJ, Pruett TL, Sawyer RG: Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 2004, 32: 53-60. 10.1097/01.CCM.0000104463.55423.EFCrossRefPubMed
76.
van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, Bonten MJ: Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med 2005, 171: 480-487. 10.1164/rccm.200401-070OCCrossRefPubMed
77.
Warren DK, Hill HA, Merz LR, Kollef MH, Hayden MK, Fraser VJ, Fridkin SK: Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med 2004, 32: 2450-2456. 10.1097/01.CCM.0000147685.79487.28CrossRefPubMed
78.
Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996, 40: 691-695.PubMedCentralPubMed
79.
Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe pneumonia. Crit Care Med 2003, 31: 2102-2106. 10.1097/01.CCM.0000069734.38738.C8CrossRefPubMed
80.
Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, et al.: Continuous versus intermittant infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45: 2460-2467. 10.1128/AAC.45.9.2460-2467.2001PubMedCentralCrossRefPubMed
81.
Lipman J, Wallis SC, Rickard C: Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43: 2559-2561.PubMedCentralPubMed
82.
Moore RD, Lietman PS, Smith CR: Clinical response to amino-glycoside therapy: the importance of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155: 93-99.CrossRefPubMed
83.
Blaser J, Stone BB, Groner MC, Zinner SH: Comparative study with enoxacin and netilmicin in a pharmcodynamic model to determine the importance of ratio of peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987, 31: 1054-1060.PubMedCentralCrossRefPubMed
84.
Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME: Once-daily dosing decreases renal accumulation of gen-tamicin and netilmicin. Clin Pharmacol Ther 1989, 45: 22-27.CrossRefPubMed
85.
Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ: Pharmcodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998, 42: 521-527.PubMedCentralPubMed
86.
Schentag JJ, Gilliland KK, Paladino JA: What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001, 32: S39-S46. 10.1086/319375CrossRefPubMed
Metadaten
Titel
Bench-to-bedside review: Antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit
verfasst von
Marin H Kollef
Publikationsdatum
01.10.2005
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 5/2005
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc3757

Weitere Artikel der Ausgabe 5/2005

Critical Care 5/2005 Zur Ausgabe

Research

Circulating anions usually associated with the Krebs cycle in patients with metabolic acidosis

Review

Year in review: Critical Care 2004 – nephrology

Commentary

The role of leadership in overcoming staff turnover in critical care

Research

A systematic evaluation of the quality of meta-analyses in the critical care literature

Review

Clinical review: Role of triggering receptor expressed on myeloid cells-1 during sepsis

Commentary

Recently published papers: What not to do and how not to do it?

Neu im Fachgebiet AINS

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise